Replies to post #470787 on NorthWest Biotherapeutics Inc (NWBO)

[StonkMaster]

Embargo due to publication

[Survivor2012]

I asked that question to DI yesterday and he said that results were disseminated in slide deck attached to last PR: "The slide deck was available concurrently with the presentation. We put the link in the PR sent this morning. If you haven't seen it, do download it. Very rich with information."

[MI Dendream]

Pins and needles

Since they made the presentation available from a link on their website simultaneously with the actual presentation they do not need to release a PR to meet reporting requirements. My guess is they will hold the PR until after hours or the morning of the publication release.

The real qustion is given the results we saw yesterday why not release the data 16-17 months ago, or at least at SNO last year given the fact that they had the data in hand shortly after locking the database on October 5, 2020?

Well, we know that it hit on the two big one the primary OS outcome in ndGBM and secondary rGBM. We also know that they were willing to present the data before publishing it. LL presenting at SNO would have been as credible as at NYAS with the most targeted provider audience for your product and more press than NYAS produced. Hee are a few ideas:
- NYAS was in the big boys back yard, both pharma and Wallstreet
- LP and LG had said they would have several rapid fire press releases in a short window of time to counter the expect sell attack that we saw yesterday
- Annals of Oncology publishes their June edition tomorrow which os 10 days delayed and thus conveniently right after NYAS.
- May is Brain Cancer awareness month
- we would be foolish to believe the publication can counter the attack that was initiated by the presentation so there must be more to the plan than that.
- I have previously reported my logic for why I think approvals are pending. Now, we know that the missed PFS endpoint that was expected by most likely prevented a priori analysis of the other endpoints, but that does not mean they were not performed, can’t be published, or weren’t considered by the regulators.
- I believe the ‘mixed’ result would lead them to want to ensure approval before releasing the new SAP analysis for fear of many things. If they were looking for just appeasing shareholders and Wallstreet, why wait so darn long?
- They need cash, but yesterday’s action doesn’t make the pricing of an offer very favorable. Given how shrewd LP has been regarding capital creation, I think it is obvious that she has another plan and multiple alternatives.

My conclusion, the June 4th ASCO presentation will discuss bigger news that the great data that we saw yesterday. Either buy-out/partnership, approvals. or both.

Pins and needles folks, pins and needles